ReviewFuture virology2023
Natural killer cells in COVID-19: from infection, to vaccination and therapy.
Review in Future virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Effect of Aptamin C on NK Cell Activity and Cytotoxicity: A Randomized Placebo-Controlled Trial and In Vitro Comparison with Vitamin C.Antioxidants (Basel, Switzerland) · 2026Article
- Widespread gene-environment interactions shape the immune response to SARS-CoV-2 infection in hospitalized COVID-19 patients.Nature communications · 2026Article
- Mapping NK cell diversity in response to COVID-19 and mRNA vaccination.Scientific reports · 2025Article
- NK Cells: A Powerful Squad Versus SARS-CoV-2.International journal of molecular sciences · 2025Review
- Article
- Cxcl10 is protective during mouse-adapted SARS-CoV-2 infection.Journal of leukocyte biology · 2025Article
- Distinct immunity dynamics of natural killer cells in mild and moderate COVID-19 cases during the Omicron variant phase.Frontiers in immunology · 2025Observational
- Off-the-shelf allogeneic natural killer cells for the treatment of COVID-19.Molecular therapy. Methods & clinical development · 2024Article
- Cxcl10 is required for survival during SARS-CoV-2 infection in mice.bioRxiv : the preprint server for biology · 2024Article
- Low-frequency CD8NPJ vaccines · 2024Article
- Integrative genomic analysis of the lung tissue microenvironment in SARS-CoV-2 and NL63 patients.Heliyon · 2024Article
- Delineating immune variation between adult and children COVID-19 cases and associations with disease severity.Scientific reports · 2024Article
- Unraveling the dynamic mechanisms of natural killer cells in viral infections: insights and implications.Virology journal · 2024Review
- Measurement of IFN-γ and IL-2 for the assessment of the cellular immunity against SARS-CoV-2.Scientific reports · 2024Article
- Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus.Frontiers in immunology · 2024Article
- Post-COVID-19 and Post-COVID-19 Vaccine Arthritis, Polymyalgia Rheumatica and Horton's Arteritis: A Single-Center Assessment of Clinical, Serological, Genetic, and Ultrasonographic Biomarkers.Journal of clinical medicine · 2023Article
- Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.Frontiers in immunology · 2023Review
- COVID-19 associated with cryptococcosis: a scoping review.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells are among the most important innate immunity members, which are the first cells that fight against infected cells. The function of these cells is impaired in patients with COVID-19 and they are not able to prevent the spread of the disease or destroy the infected cells. Few studies have evaluated the effects of COVID-19 vaccines on NK cells, though it has been demonstrated that DNA vaccines and BNT162b2 can affect NK cell response. In the present paper, the effects of SARS-CoV-2 on the NK cells during infection, the effect of vaccination on NK cells, and the NK cell-based therapies were reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.